Generali Investments Management Co LLC Decreases Stake in Revvity, Inc. (NYSE:RVTY)

Generali Investments Management Co LLC decreased its position in Revvity, Inc. (NYSE:RVTY) by 55.0% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 1,551 shares of the company’s stock after selling 1,896 shares during the period. Generali Investments Management Co LLC’s holdings in Revvity were worth $164,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Assetmark Inc. lifted its stake in shares of Revvity by 3,700.0% during the 4th quarter. Assetmark Inc. now owns 266 shares of the company’s stock valued at $30,000 after buying an additional 259 shares in the last quarter. Optiver Holding B.V. purchased a new stake in Revvity in the 4th quarter worth approximately $33,000. Quarry LP increased its holdings in shares of Revvity by 45.7% in the 4th quarter. Quarry LP now owns 303 shares of the company’s stock worth $34,000 after buying an additional 95 shares during the last quarter. Millstone Evans Group LLC bought a new position in shares of Revvity in the 4th quarter worth $38,000. Finally, Vermillion Wealth Management Inc. bought a new position in shares of Revvity in the 4th quarter worth $41,000. 86.65% of the stock is owned by institutional investors.

Revvity Stock Performance

Shares of RVTY stock opened at $91.99 on Friday. The company has a 50 day moving average price of $93.51 and a 200-day moving average price of $107.48. Revvity, Inc. has a 52 week low of $87.70 and a 52 week high of $129.50. The firm has a market capitalization of $10.84 billion, a PE ratio of 41.63, a P/E/G ratio of 3.82 and a beta of 0.97. The company has a quick ratio of 3.03, a current ratio of 3.60 and a debt-to-equity ratio of 0.41.

Revvity (NYSE:RVTY) last announced its quarterly earnings results on Monday, April 28th. The company reported $1.01 EPS for the quarter, topping analysts’ consensus estimates of $0.96 by $0.05. The firm had revenue of $664.76 million during the quarter, compared to analyst estimates of $662.30 million. Revvity had a net margin of 9.81% and a return on equity of 7.68%. The business’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.98 earnings per share. As a group, equities research analysts expect that Revvity, Inc. will post 4.94 earnings per share for the current year.

Revvity Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 8th. Investors of record on Friday, July 18th will be given a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, July 18th. This represents a $0.28 annualized dividend and a yield of 0.30%. Revvity’s dividend payout ratio (DPR) is 11.91%.

Analyst Ratings Changes

RVTY has been the topic of several recent research reports. Robert W. Baird reduced their target price on shares of Revvity from $127.00 to $125.00 and set an “outperform” rating on the stock in a report on Tuesday, April 29th. JPMorgan Chase & Co. cut their price target on shares of Revvity from $120.00 to $100.00 and set a “neutral” rating on the stock in a report on Tuesday, April 29th. Raymond James reaffirmed an “outperform” rating and issued a $120.00 target price (down from $145.00) on shares of Revvity in a research report on Tuesday, April 29th. UBS Group raised shares of Revvity from a “neutral” rating to a “buy” rating and dropped their target price for the stock from $145.00 to $115.00 in a research report on Thursday, May 1st. Finally, The Goldman Sachs Group lowered their price target on shares of Revvity from $140.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, April 29th. Five equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $125.64.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.